The global preimplantation genetic diagnosis (PGD) market size was valued at $81.52 million in 2020, and is projected to reach $217.18 million by 2030, registering a CAGR of 10.3% from 2021 to 2030. Preimplantation genetic diagnosis (PGD) is called as embryo screening. It is a branch of genetics that involves genetic testing of embryos through in vitro fertilization (IVF).
PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders, including spinal muscular atrophy and cystic fibrosis.
PGD provides effective solution for healthy embryos free from genetic, hereditary, and chromosomal disorders. It is an evolving technique in modern genetic study. In addition, increase in prevalence of hereditary, chromosomal, and genetic disorders every year that include triploidy, thalassemia, and Duchenne muscular dystrophy (DMD)requires PGD for the diagnosis of mutational changes. Moreover, increase in usage of PGD techniques in selecting human leukocyte antigen (HLA) profile to match existing sibling with disease and sex balancing in family spurred the growth of PGD market. Furthermore, growth in infertility rate and increase in awareness regarding PGD technique boost the growth of the market.
The global PGD market is segmented on the basis of test type and region. By test type, the market is classified into chromosomal abnormalities, aneuploidy, X-linked diseases, single gene disorders, HLA typing, gender selection, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market.
The major market participants profiled in this report include Agilent Technologies, Inc., CeGaT GmbH, Illumina Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Natera Inc., PacGenomics, PerkinElmer, Inc., Quest Diagnostics Inc., and Reproductive Genetic Innovations (RGI)
PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders, including spinal muscular atrophy and cystic fibrosis.
PGD provides effective solution for healthy embryos free from genetic, hereditary, and chromosomal disorders. It is an evolving technique in modern genetic study. In addition, increase in prevalence of hereditary, chromosomal, and genetic disorders every year that include triploidy, thalassemia, and Duchenne muscular dystrophy (DMD)requires PGD for the diagnosis of mutational changes. Moreover, increase in usage of PGD techniques in selecting human leukocyte antigen (HLA) profile to match existing sibling with disease and sex balancing in family spurred the growth of PGD market. Furthermore, growth in infertility rate and increase in awareness regarding PGD technique boost the growth of the market.
The global PGD market is segmented on the basis of test type and region. By test type, the market is classified into chromosomal abnormalities, aneuploidy, X-linked diseases, single gene disorders, HLA typing, gender selection, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market.
Competition Analysis
The major market participants profiled in this report include Agilent Technologies, Inc., CeGaT GmbH, Illumina Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Natera Inc., PacGenomics, PerkinElmer, Inc., Quest Diagnostics Inc., and Reproductive Genetic Innovations (RGI)
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the preimplantation genetics diagnosis market analysis from 2020 to 2030 to identify the prevailing preimplantation genetics diagnosis market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the preimplantation genetics diagnosis (pgd) market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- The key players within preimplantation genetics diagnosis industry are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the preimplantation genetics diagnosis industry.
- The report includes the analysis of the regional as well as global preimplantation genetics diagnosis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Test Type
- Chromosomal Abnormalities
- Aneuploidy
- X-linked diseases
- Single Gene Disorders
- HLA Typing
- Gender selection
- Others
By Region
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Rest Of Asia Pacific
- LAMEA
- Latin America
- Middle East
- Africa
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Rest of Europe
Key Market Players
- Agilent Technologies, Inc.
- cegat gmbh
- Illumina Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Natera Inc.
- pacgenomics
- PerkinElmer, Inc.
- Quest Diagnostics Inc.
- Reproductive Genetic Innovations (RGI)
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE
CHAPTER 5: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION
CHAPTER 6: COMPANY LANDSCAPE
CHAPTER 7: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Preimplantation Genetics Diagnosis (PGD) Market,' the preimplantation genetics diagnosis (pgd) market was valued at $81,520.20 thousand in 2020, and is estimated to reach $217,190.00 thousand by 2030, growing at a CAGR of 10.4% from 2021 to 2030.Depending on test type, the market is segmented on the basis of chromosomal abnormalities, aneuploidy, X-linked diseases, single gene disorders, human leukocyte antigens (HLA) typing, gender selection, and others. The chromosomal abnormalities segment accounted for the highest market share in 2020 and single gene disorders is expected to witness significant growth during the forecast period, owing to rise in number of patients suffering from genetic disorders. The market is mainly driven by increase in awareness regarding embryo genetic testing. In addition, rise in infertility rate and surge in hereditary diseases positively influenced the growth of the market. However, high costs involved for various diagnosis can hinder the growth of preimplantation genetics diagnosis market size.
In 2020, North America dominated the global PGD market, in terms of revenue, accounting for around 40% share of the radiology information system industry, followed by Europe and Asia-Pacific. Moreover, the market in Asia-Pacific is growing with high CAGR, owing to increased adoption of in vitro fertilization (IVF).
PGD is extensively used in ivf genetic testing for identification of genetic defects in embryos. PGD is effective in reducing chances of conceiving unhealthy embryos. In addition, it significantly increases the chances of successful healthy pregnancy. These factors drive the growth of the market. Furthermore, rise in infertility rate as well as genetic, hereditary, and chromosomal diseases positively influenced the growth of the market. In addition, technological advancements in PGD provide advantages, including ability to prevent disability in offspring and development of unhealthy savior siblings by using PGD with HLA. Furthermore, PGD shown positive response in patients trying to conceive with recurrent IVF failures, low sperm count, and with advance maternal age.
Furthermore, preimplantation genetics diagnosis market share is anticipated to grow rapidly throughout the forecast period, owing to increase in use of assisted reproductive technology (ART) in developed countries.
For instance, according to the U.S. Department of Health & Human Services, as of 2019, there are 489 fertility clinics in the U.S. that are involved in providing ART solutions. States including Massachusetts, Columbia, and New Jersey have the highest proportion of ART births. In addition, increase in awareness regarding healthy embryos in developing countries is expected to be a preimplantation genetic diagnosis market opportunity.
However, during the pandemic lockdown, various players in the PGD market reduced their business in countries, including China, the U.S., and India, owing to disruption of supply chain. This break directly impacted companies involved in providing PGD. In addition, extensive focus of major countries on development of vaccines negatively influenced the growth of the market. However, reopening of diagnostic facilities and introduction of vaccines for coronavirus disease boost the preimplantation genetics diagnosis market size.
The key players profiled in the PGD market report include Agilent Technologies, Inc., CeGaT GmbH, Illumina Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Natera Inc., PacGenomics, PerkinElmer, Inc., Quest Diagnostics Inc., and Reproductive Genetic Innovations (RGI).
Key findings of the Study
- The report provides an extensive analysis of the current and emerging preimplantation genetics diagnosis market trends and dynamics.
- Depending on test type, the chromosomal abnormalities dominated the PGD market, in terms of revenue in 2020 and the single gene disorders segment is projected to grow at a significant CAGR during the forecast period.
- Asia-Pacific is projected to register highest growth rate in the coming years.
The report provides an extensive analysis of the current trends and emerging opportunities of the market.
In-depth preimplantation genetics diagnosis market analysis is conducted by constructing estimations for the key segments between 2021 and 2030.
Companies Mentioned
- Agilent Technologies, Inc.
- cegat gmbh
- Illumina Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Natera Inc.
- pacgenomics
- PerkinElmer, Inc.
- Quest Diagnostics Inc.
- Reproductive Genetic Innovations (RGI)
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 81.52 million |
| Forecasted Market Value ( USD | $ 217.18 million |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
